Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
Source: SeekingAlpha
2025-06-06 11:09:17 ET
Investment Overview
When I last covered Autolus Therapeutics plc ( AUTL ) for Seeking Alpha back in September last year, it was to make a Bull case for its shares, based on the UK-based biotech's upcoming PDUFA date for its autologous CAR-T cell therapy, obecabtagene autoleucel ("obe-cel"), in patients with relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (B-ALL)....
Read the full article on Seeking Alpha
For further details see:
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
Cabaletta Bio Inc.
NASDAQ: CABA
CABA Trading
-6.27% G/L:
$3.065 Last:
867,569 Volume:
$3.20 Open:
CABA Latest News
February 24, 2026 08:00:00 am
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
February 05, 2026 08:00:00 am
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
November 10, 2025 07:30:00 am
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
CABA Stock Data
$250,770,856
85,435,369
1.33%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
Philadelphia
